Search

Interdisciplinary approach to CKM care

Explore the global impact of Cardiovascular- Kidney- Metabolic (CKM) syndrome, and the need for an integrated approach to manage these interconnected conditions. Insights from experts at Boehringer Ingelheim and George Washington University.

Health disparities in Black and African Americans

Addressing social determinants of health in cardio-kidney-metabolic care

Dr. Anna Dieckmann and Dr. Lorenz Maier

Here is the story of Dr. Anna Dieckmann and Dr. Lorenz Maier's successful partnership. For more talent insights, visit our Careers Page.

Anna Dieckmann

Anna Dieckmann talks about professional fulfilment and possibilities for the future in her role in Information Technology.

New Swine Vaccine Combination Released | Boehringer Ingelheim US

Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.

Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US

Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US

Click here to find out more about Boehringer Ingelheim's 3FLEX® 250-Dose option & new vaccine mixing procedures, preventing major swine respiratory disease.

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

New effort to help improve C-R-M health outcomes

Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)

Introducing Ingelvac Provenza™ | Boehringer Ingelheim US

Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

How Much Do You Know About PPID? | Boehringer Ingelheim US

Click here to find out more about some of the common misconceptions you might have about pituitary pars intermedia dysfunction (PPID).

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Striving to revolutionize mental health research

World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Reducing Stress in Horses – With Music

Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".

Redefining mental health to enable people to thrive

At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers